Literature DB >> 27067877

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.

Elizabeth Hansen1, Deepak Sahasrabudhe2, Lynn Sievert2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27067877     DOI： 10.1007/s00262-016-1835-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  23 in total

Review 1.  Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.

Authors:  Z Quandt; A Young; M Anderson
Journal:  Clin Exp Immunol       Date:  2020-02-28       Impact factor: 4.330

2.  Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.

Authors:  V Venetsanaki; A Boutis; A Chrisoulidou; P Papakotoulas
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

3.  Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.

Authors:  Jasna Aleksova; Peter K H Lau; Georgia Soldatos; Grant McArthur
Journal:  BMJ Case Rep       Date:  2016-11-23

4.  Hyperosmolar Hyperglycaemic State and Diabetic Ketoacidosis in Nivolumab-Induced Insulin-Dependent Diabetes Mellitus.

Authors:  Ahmed Osman Saleh; Ruba Taha; Shehab Fareed A Mohamed; Mohammed Bashir
Journal:  Eur J Case Rep Intern Med       Date:  2021-08-13

5.  New onset diabetes after nivolumab treatment.

Authors:  Ricardo Capitao; Carlos Bello; Ricardo Fonseca; Catarina Saraiva
Journal:  BMJ Case Rep       Date:  2018-01-29

Review 6.  Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors:  Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

Review 7.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 8.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

Review 9.  Endocrine toxicities of immune checkpoint inhibitors.

Authors:  Jordan J Wright; Alvin C Powers; Douglas B Johnson
Journal:  Nat Rev Endocrinol       Date:  2021-04-19       Impact factor: 43.330

10.  Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management.

Authors:  Jonathan Kapke; Zachary Shaheen; Deepak Kilari; Paul Knudson; Stuart Wong
Journal:  Case Rep Oncol       Date:  2017-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.